Saskia Middeldorp
@middeldorps.bsky.social
Head Department of Internal Medicine at Radboudumc, Nijmegen 🇳🇱. Professor fighting venous thromboembolism. Pregnancy, thrombosis, thrombophilia. Elected council member of ISTH. Feminist with ❤️ husband & 3 sons. 🚴🏼♀️🏃🏻♀️. #Hemesky #Thrombosky
Not yet published in full!
June 25, 2025 at 12:41 PM
Not yet published in full!
Wow that’s pretty high!
June 24, 2025 at 8:53 PM
Wow that’s pretty high!
Thanks! I couldn’t make it to the presentation. So, no capping at a maximum dose was applied?
June 24, 2025 at 7:26 PM
Thanks! I couldn’t make it to the presentation. So, no capping at a maximum dose was applied?
The apicat trial did study apixaban dose reduction VS full dose. That study makes me very comfortable using apixaban in this setting
June 24, 2025 at 12:20 PM
The apicat trial did study apixaban dose reduction VS full dose. That study makes me very comfortable using apixaban in this setting
Hope you feel better!
June 24, 2025 at 3:11 AM
Hope you feel better!
In my experience, young people who don’t take any other meds and are in for the really long term sec prevention, have difficulty being adherent to the evening dose of apixaban
June 23, 2025 at 9:24 PM
In my experience, young people who don’t take any other meds and are in for the really long term sec prevention, have difficulty being adherent to the evening dose of apixaban
This was observed during the first 3 months after acute VTE. I’d like to keep the rivaroxaban option for extended treatment for patients who value the once daily regimen and are at low bleeding risk.
June 23, 2025 at 3:39 PM
This was observed during the first 3 months after acute VTE. I’d like to keep the rivaroxaban option for extended treatment for patients who value the once daily regimen and are at low bleeding risk.